The Latest Cardiac and Vascular News
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs were […]
IRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021. Second Quarter Revenue […]
– Revenues Increased 41% Year-over-Year to $12.6 Million – – U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million – – Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT […]
– Company established with world-class research from leading academia and industry leaders– Lead program targets a novel kinase involved in cellular stress response – Experienced and proven team advancing therapies for Long QT Syndrome and resistant cancers LAVAL, QC, Aug. 10, 2021 /PRNewswire/ – LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the […]
EDEN PRAIRIE, Minn., Aug. 10, 2021 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2021, which included the following highlights: Reported record quarterly revenue of $2.5 million, a 35 percent increase compared to the prior year period Realized strong sequential […]
ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021. “Renewed global adoption of robotic systems continues to drive robust double digit revenue growth for Stereotaxis,” […]
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunity Resubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder Improved balance sheet with private placement and increased financial discipline Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation […]
Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid […]
SILVER SPRING, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and six months ended June 30, 2021. Recent […]
— Leaders in the fields of RNA and cardiovascular disease join HAYA to advance its pipeline of therapeutics targeting long non-coding RNAs — LAUSANNE, Switzerland–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its […]
